Three new SHIKARI® ELISA kits for semi-quantitative measurement of total anti-drug antibodies to infliximab , infliximab-biosimilar CT-P13 and adalimumab

We have been in the field of medical biotechnology for 15 years. As we are the first company to bring biological drug monitoring kits to the market for clinical laboratories, clinicians and their patients and pharmaceutical companies who have been used and/or using our products with confidence since 2008. Until now a total of 36 kits for 15 biological drugs have been brought to the market and our SHIKARI ELISA^® kits have been used in 71 scientific papers.

Matriks Biotek^® is committed to research and development in addition to advancing product innovation at every turn. As a result of these; Our products on the market are consistently increasing. We have recently completed 3 new products for screening total anti-drug antibody to infliximab (Remicade), infliximab biosimilar CT-P13 (Remsima/Inflektra) and adalimumab (Humira); SHIKARI Q-ATI Total, SHIKARI S-AIR Total and S-ATA Total respectively and will be launched on coming days.


Visit our website for information about all of our products www.matriksbiotek.com
Ask information from info@matriksbiotek.com or a quote from order@matriksbiotek.com 

Specifications of the tests: